Amylyx Pharmaceuticals vs Bicycle Therapeutics
AMLX and BCYC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMLX and BCYC compare
Amylyx Pharmaceuticals is the larger company, worth 14 times as much as Bicycle Therapeutics ($3.3B against $242M).
Bicycle Therapeutics scores higher on the StockData Score (11 against 7 for Amylyx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMLX | BCYC |
|---|---|---|
| Size and price | ||
| Market cap | $3.3B | $242M |
| Share price | $29.86 | $3.45 |
| Change, 1 year | 135% | −49.5% |
| Change, 5 years | 178% | −94.1% |
| Beta (5Y) | 1.15 | 1.37 |
| Employees | 136 | 288 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.9× |
| P/B | 4.4× | 0.5× (better) |
| FCF yield | – | −73.2% |
| Fair value | – | $16.21 |
| Margin of safety | – | 78.7% |
| Growth | ||
| Revenue growth (TTM) | – | 195% |
| Revenue growth, 5Y average | – | 47.5% |
| Profitability | ||
| Operating margin | – | −189% |
| Net margin | – | −170% |
| FCF margin | – | −212% |
| Return on equity | −30.1% | −25.2% (better) |
| Return on invested capital | – | −4543% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −815.6× |
| Current ratio | 26.81 (better) | 12.09 |
| Altman Z-score | 59.22 (better) | 0.09 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 53.4% |
| Held by insiders | 8.0% | 21.3% |
| Insider net buying, 12 months | −$10.0M | −$523K (better) |
| Short interest, % of float | 12.5% | – |
Go deeper
- AMLX stock overview
- AMLX income statement
- AMLX valuation and score
- BCYC stock overview
- BCYC income statement
- BCYC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.